In the Claims:

Please cancel claims 3 and 5-25.

Please amend claims 1, 2, and 4 as follows:

--1. (Amended) A method of inhibiting the differentiation of an activated T-cell into a cytotoxic lymphocyte in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of a P- selectin glycoprotein ligand (PSGL) antagonist.--

--2. (Amended) The method of claim 1, wherein said P- selectin glycoprotein ligand (PSGL) antagonist is selected from the group consisting of a soluble form of PSGL, an antibody directed to PSGL, an antibody directed to sLe_x, an antibody directed to sulfated tyrosine, sLe_x, mimetics which inhibit sLe_x binding and a small molecule inhibitor of PSGL binding.--

--4. (Amended) The method of claim 2, wherein said PSGL antagonist is an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.--

Please add new claims 26-34 as follows:

--26. (New) The method of claim 4, wherein said antibody is a monoclonal antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.--

--27. (New) The method of claim 4, wherein said antibody is administered in a pharmaceutically acceptable formulation.--

--28. (New) A method for treating or ameliorating, in a subject, a disease or condition resulting from differentiation of activated T-cells into cytotoxic lymphocytes comprising administering to said subject a therapeutically effective amount of an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof.--

--29. (New) The method of claim 28, wherein said disease or condition is an autoimmune condition.--

--30. (New) The method of claim 28, wherein said disease or condition is an allergic reaction.--

--31. (New) The method of claim 28, wherein said disease or condition is asthma.--

--32. (New) The method of claim 28, wherein said antibody is a monoclonal antibody, or a fragment thereof. --

--33. (New) The method of claim 28, wherein said subject is a mammalian subject.--

--34. (New) The method of claim 28, wherein said antibody is administered in a pharmaceutically acceptable formulation.--